Inactive Instrument

Insiders La Jolla Pharmaceutical Company

Equities

LJPC

US5034596040

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

La Jolla Pharmaceutical Announces Management Changes	22-08-22	CI
Insider Sell: La Jolla Pharmaceutical	21-12-02	MT
La Jolla Pharmaceutical : Names Tony Hodges Chief Medical Officer	21-09-10	MT
La Jolla Pharmaceutical : Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company	21-09-10	PU
La Jolla Pharmaceutical Company Appoints Tony Hodges, M.D., Facp, Fccp, as Chief Medical Officer	21-09-10	CI
Insider Trends: Insider Buying Added to with Purchase of La Jolla Pharmaceutical Co Shares	21-06-01	MT
Insider Trends: Insider Purchase Adds to La Jolla Pharmaceutical Co Positive Trend	21-05-26	MT
La Jolla Pharmaceutical Company Appoints Larry Edwards to Serve as a Member of the Board	20-10-30	CI
La Jolla Pharmaceutical Company Announces Management Changes	20-10-02	CI
La Jolla Pharmaceutical Company Announces Resignation of Lakhmir Chawla as Chief Medical Officer	20-09-17	CI
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company	20-07-28	GL
Larry Edwards Appoints Larry Edwards as President	20-07-28	CI
La Jolla Pharmaceutical Company Appoints Larry Edwards as Chief Executive Officer	20-07-28	CI
La Jolla Pharmaceutical Company Announces Executive Changes	20-06-02	CI
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany	20-04-07	GL
La Jolla Pharmaceutical Company : to Provide GIAPREZA for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford	20-04-07	AQ
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom	20-04-06	GL
La Jolla Pharmaceutical Company : to Provide GIAPREZA for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany	20-04-06	AQ
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany	20-04-03	GL
La Jolla Pharmaceutical Company : to Provide GIAPREZA for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19	20-04-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders La Jolla Pharmaceutical Company

Equities

LJPC

US5034596040

Insiders

Filters